Vaxcyte, Inc.
Vaxcyte is a clinical-stage vaccine company based in San Carlos, California. It develops conjugate and protein vaccine candidates against bacterial diseases for adults and children, using its XpressCF cell-free protein synthesis platform. Its pneumococcal conjugate vaccine candidates include VAX-31, which is in clinical development for adults and children, VAX-24 for infants and VAX-XL. The company also develops VAX-A1 against Group A Strep and the preclinical candidate VAX-GI against dysentery and shigellosis. VAX-GI is developed with the University of Maryland, Baltimore and receives partial funding from two National Institutes of Health research grants. Vaxcyte also has discovery-stage vaccine programs.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Vaxcyte reported a Q3 GAAP loss of $1.99 per share, exceeding estimates by 15 cents. The company's cash, cash equivalents, and investments were $2.26 billion as of Sept. 30, down from $2.44 billion at the end of 2022.
Vaxcyte (PCVX) reported Q3 GAAP EPS of -$1.99, beating estimates by $0.15. The company had $2.26B in cash and investments as of September 30, 2026, down from $2.44B at the end of 2025, before a $1.1B offering in October 2026.
Vaxcyte reported Q3 2026 results, highlighting positive topline data from the OPUS-1 Phase 3 trial of VAX-31, meeting all primary endpoints. The company expects results from OPUS-2 and OPUS-3 trials in early 2027, supporting a BLA submission in 2028. Vaxcyte also announced progress in its VAX-31 infant indication and VAX-A1 Phase 1 study. As of September 30, 2026, the company had $3.4 billion in cash and investments.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning PCVX (Vaxcyte, Inc.). Coverage has skewed bullish: 5 bullish, 0 neutral, and 1 bearish.
Recent PCVX coverage spans earnings, financial news and technology.
In the last 30 days, PCVX insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($320K). The most active reporter was Wassil Jim, EVP, Chief Scientific Ofc, COO, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Vaxcyte reported a Q3 GAAP loss of $1.99 per share, exceeding estimates by 15 cents. The company's cash, cash equivalents, and investments were $2.26 billion as of Sept. 30, down from $2.44 billion at the end of 2022.
Earnings beat may lift sentiment and support the stock.
Positive pivotal trial data is likely to lift the stock on expectations of a BLA filing and future commercial launch.
Analyst upgrade and higher target suggest upside pressure.
The large capital raise creates dilution and added debt, likely pressuring the share price.
AlphAI scores every news story that mentions PCVX with an AI model for sentiment and relevance, and aggregates insider trades from Vaxcyte, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vaxcyte reported a Q3 GAAP loss of $1.99 per share, exceeding estimates by 15 cents. The company's cash, cash equivalents, and investments were $2.26 billion as of Sept. 30, down from $2.44 billion at the end of 2022.
Vaxcyte (PCVX) reported Q3 GAAP EPS of -$1.99, beating estimates by $0.15. The company had $2.26B in cash and investments as of September 30, 2026, down from $2.44B at the end of 2025, before a $1.1B offering in October 2026.
Vaxcyte reported Q3 2026 results, highlighting positive topline data from the OPUS-1 Phase 3 trial of VAX-31, meeting all primary endpoints. The company expects results from OPUS-2 and OPUS-3 trials in early 2027, supporting a BLA submission in 2028. Vaxcyte also announced progress in its VAX-31 infant indication and VAX-A1 Phase 1 study. As of September 30, 2026, the company had $3.4 billion in cash and investments.
Cantor Fitzgerald reiterated an Overweight rating on Vaxcyte (PCVX) with a $120 price target, citing OPUS-1 data and $1B financing. The firm raised adult success probability to 90% and noted potential upside to $90. The stock has declined 10% in a week but gained 50% over a year. Multiple analysts updated targets post-trial results.
Vaxcyte (PCVX) shares fell after raising $1.15 billion via a stock and convertible notes offering, causing investor concerns about dilution and hedging. Despite strong Phase 3 results for its VAX-31 vaccine, the company remains pre-revenue and faces risks related to cash burn and debt. PCVX has a market cap of $10.27B and is up 37.88% YTD.
Vaxcyte's VAX-31 met all primary endpoints in a phase 3 trial, showing noninferiority and superiority against competitors PCV20 (Pfizer) and PCV21 (Merck). The vaccine was well-tolerated, with safety profiles similar to licensed vaccines. Vaxcyte plans to submit a BLA in 2028, targeting a market with expanded adult vaccination recommendations.
Vaxcyte Inc. (PCVX) stock has surged over 100% in 2026 due to advancements in its pneumococcal vaccine programs. Key developments include Phase 3 trial initiations and positive data for VAX-31. The stock reached a high of $90.75 in October 2026 and currently trades around $65. Upcoming catalysts include data from ongoing trials in 2027.
Vaxcyte (PCVX) shares fell 5.4% due to dilution concerns from a $1.15B financing round. The company raised funds via equity and convertible notes, with proceeds earmarked for clinical development and commercial prep. Insiders sold shares, while hedge funds showed mixed activity. Topline trial data is expected by late October 2026.
Cantor Fitzgerald reiterated its Overweight rating for Vaxcyte (PCVX) with a $120.00 price target. The company has a $10.62B market cap, negative earnings, and a GF Score of 36/100. Insiders sold $6.32M in shares over three months. Analysts see growth potential in its vaccine candidates, but profitability and growth remain challenges.
Vaxcyte's EVP and COO Jim Wassil sold 18,000 shares for $1.56m at $86.74 each on Oct 5, 2026, and acquired 18,000 shares via option exercise. He now holds 145,435 shares. Vaxcyte's OPUS-1 trial succeeded, with analysts raising price targets to $125-$146. The stock is down to $71.38 but up 63% over a year.
